Effective Inhibition of TDP-43 Aggregation by Native State Stabilization
Preventing the misfolding or aggregation of transactive response DNA binding protein with 43 kDa (TDP-43) is the most actively pursued disease-modifying strategy to treat amyotrophic lateral sclerosis and other neurodegenerative diseases. In this work, we provide proof of concept that native state stabilization of TDP-43 is a viable and effective strategy for treating TDP-43 proteinopathies. Firstly, we leveraged the Cryo-EM structures of TDP-43 fibrils to design C-terminal substitutions that disrupt TDP-43 aggregation. Secondly, we showed that these substitutions (S333D/S342D) stabilize monomeric TDP-43 without altering its physiological properties. Thirdly, we demonstrated that binding native oligonucleotide ligands stabilized monomeric TDP-43 and prevented its fibrillization and phase separation in the absence of direct binding to the aggregation-prone C-terminal domain. Fourthly, we showed that the monomeric TDP-43 variant could be induced to aggregate in a controlled manner, which enabled the design and implementation of a high-throughput screening assay to identify native state stabilizers of TDP-43. Altogether, our findings demonstrate that different structural domains in TDP-43 could be exploited and targeted to develop drugs that stabilize the native state of TDP-43 and provide a platform to discover novel drugs to treat TDP-43 proteinopathies.|The aggregation of transactive response DNA binding protein with 43 kDa (TDP-43) is an essential co-pathology of many neurodegenerative diseases. Herein, we developed two strategies to stabilize the native-state TDP-43 against its aggregation, namely by phosphomimetic substitutions in the C-terminus, and by small-molecule modulation. Our results represent the first proof-of-concept study on functional TDP-43 targeting and related drug discovery.image
WOS:001120090900001
2024
63
3
e202314587
REVIEWED
Funder | Grant Number |
EPFL | |